Proteomics International Laboratories’ (Proteomics International) blood test uses biomarkers – protein ‘fingerprints’ – to diagnose oesophageal adenocarcinoma and the pre-malignant condition, Barrett’s oesophagus, with the aim of detecting the disease sooner and potentially improving health outcomes.